Nisoldipine-d6
(Synonyms: 尼索地平氘代,BAY-k 5552-d6) 目录号 : GC47776
An internal standard for the quantification of nisoldipine
Cas No.:1285910-03-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Nisoldipine-d6 is intended for use as an internal standard for the quantification of nisoldipine by GC- or LC-MS. Nisoldipine is a calcium channel inhibitor.1 It binds to calcium channels in isolated rat ventricular membranes (Kd = 0.04 nM) and inhibits calcium uptake by smooth muscle cells.1,2 Nisoldipine inhibits acetylcholine-induced contraction of isolated rabbit coronary arteries (IC50 = 0.03 nM).1 In vivo, nisoldipine (3 mg/kg) reduces ventricular tachycardia and fibrillization and increases survival in a rat model of ventricular arrhythmias induced by myocardial ischemia.3 Dietary administration of nisoldipine (50-100 mg/kg) reduces systolic blood pressure in spontaneously hypertensive rats.4 Formulations containing nisoldipine have been used in the treatment of hypertension.
1.Knorr, A.The pharmacology of nisoldipineCardiovasc. Drugs Ther.1(4)393-402(1987) 2.Janis, R.A., Shrikhande, A.V., Greguski, R., et al.Review of nisoldipine binding studiesNisoldipine 198727-35(1987) 3.Fagbemi, O., and Parratt, J.R.Suppression by orally-administered nifedipine, nisoldipine and niludipine of early, life-threatening ventricular arrhythmias resulting from acute myocardial ischaemiaBr. J. Pharmacol.74(1)12-14(1981) 4.Stasch, J.-P., Kazda, S., Hirth, C., et al.Role of nisoldipine on blood pressure, cardiac hypertrophy, and atrial natriuretic peptides in spontaneously hypertensive ratsHypertension10(3)303-307(1987)
| Cas No. | 1285910-03-3 | SDF | |
| 别名 | 尼索地平氘代,BAY-k 5552-d6 | ||
| Canonical SMILES | CC(NC(C)=C1C(OCC(C([2H])([2H])[2H])C([2H])([2H])[2H])=O)=C(C(OC)=O)C1C2=C([N+]([O-])=O)C=CC=C2 | ||
| 分子式 | C20H18D6N2O6 | 分子量 | 394.5 |
| 溶解度 | Acetonitrile: Soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5349 mL | 12.6743 mL | 25.3485 mL |
| 5 mM | 0.507 mL | 2.5349 mL | 5.0697 mL |
| 10 mM | 0.2535 mL | 1.2674 mL | 2.5349 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。